Recommended dose of ROZLYTREK for adults is 600 mg orally once daily, with or without food 1

Pediatric Dosing

Temporary interruption, dose reduction, or discontinuation of treatment with ROZLYTREK may help manage adverse reactions 1

a For subsequent modifications, permanently discontinue ROZLYTREK in patients who are unable to tolerate ROZLYTREK after 2 dose reductions.
 

Congestive Heart Failure

Central Nervous System Effects

Hepatotoxicity

Hyperuricemia

QT Interval Prolongation

Vision Disorders

Anemia or Neutropenia

Other Clinically Relevant Adverse Reactions

bLevel of severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.0).
  • Dose interruptions due to adverse reactions occurred in 46% of patients. The most frequent adverse reactions (≥2%) that resulted in interruption were increased blood creatinine (4%), fatigue (3.7%), anemia (3.1%), diarrhea (2.8%), pyrexia (2.8%), dizziness (2.5%), dyspnea (2.3%), nausea (2.3%), pneumonia (2.3%), cognitive disorder (2%), and neutropenia (2%)

ALT=alanine aminotransferase; AST=aspartate aminotransferase; NTRK=neurotrophic tyrosine receptor kinase; ULN=upper limit of normal.

ROZLYTREK Safety Profile

Safety Profile

Learn about the safety profile of ROZLYTREK

ROZLYTREK Financial resources

Financial and Other Resources

Learn more about financial and other resources for ROZLYTREK

Contact a Representative

Contact a Representative

Contact your local Genentech representative for more information about ROZLYTREK